Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder

Phytotherapy Research

Volumn 29, Issue 1, 2015, Pages 17-21

  Panahi, Yunes ^a   Badeli, Roghayeh ^b   Karami, Gholam Reza ^a   Sahebkar, Amirhossein ^c,d  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Anxiety; Clinical trial; Curcumin; Depression; Piperine

Indexed keywords

ANTIDEPRESSANT AGENT; CURCUMINOID; PIPERINE; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; ALKALOID; AMIDE; CURCUMIN; PIPERIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; AFFECT; AGED; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; ANALOGS AND DERIVATIVES; ANXIETY; BIOAVAILABILITY; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE;

ADULT; ALKALOIDS; ANTIDEPRESSIVE AGENTS; ANXIETY; BENZODIOXOLES; BIOLOGICAL AVAILABILITY; CURCUMIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PSYCHIATRIC STATUS RATING SCALES;

EID: 84921031937     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5211     Document Type: Article

References (53)

1. Ak T, Gulcin I. 2008. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact 174: 27-37.
2. Atal CK, Dubey RK, Singh J. 1985. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther 232: 258-262.
3. Bergman J, Miodownik C, Bersudsky Y et al. 2013. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clin Neuropharmacol 36: 73-77.
4. Bhutani MK, Bishnoi M, Kulkarni SK. 2009. Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav 92: 39-43.
5. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV, Limtrakul P. 2004. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from turmeric powder. Biochem Pharmacol 68: 2043-2052.
6. Cheng AL, Hsu CH, Lin JK et al. 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895-2900.
7. Dowlati Y, Herrmann N, SwardfagerW et al. 2010. A meta-analysis of cytokines in major depression. Biol Psychiatry 67: 446-457.
8. Ganjali S, Sahebkar A, Mahdipour E et al. 2014. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. ScientificWorldJournal 17: 898361. DOI: 10.1155/2014/898361.
9. Gupta A, Vij G, Sharma S, Tirkey N, Rishi P, Chopra K. 2009. Curcumin, a polyphenolic antioxidant, attenuates chronic fatigue syndrome in murine water immersion stress model. Immunobiology 214: 33-39.
10. Gupta SC, Kismali G, Aggarwal BB. 2013a. Curcumin, a component of turmeric: from farm to pharmacy. Biofactors 39: 2-13.
11. Gupta SC, Patchva S, Aggarwal BB. 2013b. Therapeutic roles of curcumin: lessons learned fromclinical trials. AAPS J 15: 195-218.
12. Howren MB, Lamkin DM, Suls J. 2009. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71: 171-186.
13. Iranshahi M, Sahebkar A, Hosseini ST, Takasaki M, Konoshima T, Tokuda H. 2010. Cancer chemopreventive activity of diversin from Ferula diversivittata in vitro and in vivo. Phytomedicine 17: 269-273.
14. Kaviani H, Seyfourian H, Sharifi V, Ebrahimkhani N. 2009. Reliability and validity of Anxiety and Depression Hospital Scales (HADS): Iranian patients with anxiety and depression disorders. Tehran University Medical Journal 67: 379-385.
15. Khajuria A, Thusu N, Zutshi U. 2002. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine 9: 224-231.
16. Kulkarni SK, Bhutani MK, Bishnoi M. 2008. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl) 201: 435-442.
17. Li YC, Wang FM, Pan Y et al. 2009. Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats. Prog Neuropsychopharmacol Biol Psychiatry 33: 435-449.
18. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. 2001. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21: 8370-8377.
19. Lin TY, Lu CW, Wang CC, Wang YC, Wang SJ. 2011. Curcumin inhibits glutamate release in nerve terminals from rat prefrontal cortex: possible relevance to its antidepressant mechanism. Prog Neuropsychopharmacol Biol Psychiatry 35: 1785-1793.
20. Lopresti AL, Hood SD, Drummond PD. 2012. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol 26: 1512-1524.
21. Mohammadi A, Sahebkar A, Iranshahi M et al. 2013. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 27: 374-379.
22. Myint AM, Leonard BE, Steinbusch HW, Kim YK. 2005. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 88: 167-173.
23. Nemeroff CB. 2007. Prevalence and management of treatment-resistant depression. J Clin Psychiatry 68(Suppl 8): 17-25.
24. Panahi Y, Sahebkar A, Amiri M et al. 2012a. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nutr 108: 1272-1279.
25. Panahi Y, Sahebkar A, Parvin S, Saadat A. 2012b. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 49: 580-588.
26. Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. 2014a. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res. DOI: 10.1002/ptr.5174.
27. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. 2014b. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res. DOI: 10.1002/ptr.5149.
28. Panahi Y, Saadat A, Beiraghdar F, Hosseini Nouzari SM, Jalalian HR, Sahebkar A. 2014c. Antioxidant effects of bioavailability-enhanced curcuminoids in patientswith solid tumors:Arandomized double-blind placebo-controlled trial. J Funct Foods 6: 615-622.
29. Rajasekar N, Dwivedi S, Tota SK et al. 2013. Neuroprotective effect of curcumin on okadaic acid induced memory impairment in mice. Eur J Pharmacol 715: 381-394.
30. Sahebkar A. 2010. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 94: e75-e76; author reply e77.
31. Sahebkar A. 2013. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 39: 197-208.
32. Sahebkar A. 2014a. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 28: 633-642.
33. Sahebkar A. 2014b. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol 11: 123.
34. Sahebkar A. 2014c. Low-density lipoprotein is a potential target for curcumin: novel mechanistic insights. Basic Clin Pharmacol Toxicol 114: 437-438.
35. Sahebkar A, Mohammadi A, Atabati A et al. 2013. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 27: 1883-1888.
36. Samini F, Samarghandian S, Borji A, Mohammadi G, Bakaian M. 2013. Curcumin pretreatment attenuates brain lesion size and improves neurological function following traumatic brain injury in the rat. Pharmacol Biochem Behav 110: 238-244.
37. Sanmukhani J, Satodia V, Trivedi J et al. 2014. Efficacy and safety of curcumin in major depressive disorder: A randomized controlled trial. Phytother Res 28: 579-585.
38. Shehzad A, Lee J, Lee YS. 2013a. Curcumin in various cancers. Biofactors 39: 56-68.
39. Shehzad A, Rehman G, Lee YS. 2013b. Curcumin in inflammatory diseases. Biofactors 39: 69-77.
40. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353-356.
41. Strimpakos AS, Sharma RA. 2008. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10: 511-545.
42. Wang R, Xu Y, Wu HL et al. 2008. The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. Eur J Pharmacol 578: 43-50.
43. Wei QY, Chen WF, Zhou B, Yang L, Liu ZL. 2006. Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim Biophys Acta 1760: 70-77.
44. World Health Organization. 2008. The global burden of disease: 2004 update. Available at: http://www.who.int/healthinfo/global-burden-disease/2004-report-update/en/index.html (accessed January 04 2014).
45. Xia X, Cheng G, Pan Y, Xia ZH, Kong LD. 2007. Behavioral, neurochemical and neuroendocrine effects of the ethanolic extract from Curcuma longa L. in the mouse forced swimming test. J Ethnopharmacol 110: 356-363.
46. Xu Y, Ku BS, Yao HY et al. 2005a. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav 82: 200-206.
47. Xu Y, Ku BS, Yao HY et al. 2005b. The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol 518: 40-46.
48. Xu Y, Ku B, Cui L et al. 2007. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res 1162: 9-18.
49. Xu Y, Li S, VernonMM et al. 2011. Curcumin prevents corticosterone-induced neurotoxicity and abnormalities of neuroplasticity via 5-HT receptor pathway. J Neurochem 118: 784-795.
50. Yu ZF, Kong LD, Chen Y. 2002. Antidepressant activity of aqueous extracts of Curcuma longa inmice. J Ethnopharmacol 83: 161-165.
51. Zhou H, Beevers CS, Huang S. 2011. The targets of curcumin. Curr Drug Targets 12: 332-347.
52. Zhu YG, Chen XC, Chen ZZ et al. 2004. Curcumin protects mitochondria from oxidative damage and attenuates apoptosis in cortical neurons. Acta Pharmacol Sin 25: 1606-1612.
53. Zigmond AS, Snaith RP. 1983. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67: 361-370.